|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:acquisitionYear
|
2023
|
|
gptkbp:CEO
|
gptkb:Laurence_Reid
|
|
gptkbp:clinicalTrialPhase
|
Phase 1/2 (DB-OTO, as of 2023)
|
|
gptkbp:collaboratedWith
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:focusesOn
|
hearing loss therapies
|
|
gptkbp:foundedYear
|
2015
|
|
gptkbp:founder
|
gptkb:Robert_Langer
gptkb:David_Lucchino
gptkb:Albert_Edge
gptkb:Lee_Rubin
gptkb:Steven_Holtzman
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Decibel Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:DB-020
gptkb:DB-OTO
|
|
gptkbp:numberOfEmployees
|
approximately 60 (as of 2023)
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:specializesIn
|
precision medicine
gene therapy
biologic drugs
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:DBTX
|
|
gptkbp:target
|
cisplatin-induced hearing loss
congenital hearing loss
|
|
gptkbp:website
|
https://www.decibeltx.com/
|
|
gptkbp:bfsParent
|
gptkb:Third_Rock_Ventures
|
|
gptkbp:bfsLayer
|
6
|